226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
Showing 1 to 10 of 145 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05737121 (ClinicalTrials.gov) | March 7, 2023 | 10/2/2023 | Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or ... | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate t ... | Interstitial Cystitis;Bladder Pain Syndrome | Drug: VNX001;Drug: Placebo;Drug: Lidocaine;Drug: Heparin | Vaneltix Pharma, Inc. | Prevail Infoworks, Inc | Not yet recruiting | 18 Years | N/A | All | 120 | Phase 2 | United States |
2 | NCT05726786 (ClinicalTrials.gov) | March 2023 | 16/1/2023 | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst T ... | The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial) The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multi ... | Bladder Cancer;Interstitial Cystitis;Painful Bladder Syndrome;Neurogenic Bladder;Hemorrhagic Cystitis;Endometriosis;Bladder Disease Bladder Cancer;Interstitial Cystitis;Painful Bladder Syndrome;Neurogenic Bladder;Hemorrhagic Cystiti ... | Drug: Immunonutrition | Centre Hospitalier Universitaire Vaudois | University Hospital Inselspital, Berne;Hôpital Riviera-Chablais, Vaud-Valais | Not yet recruiting | 18 Years | N/A | All | 232 | Phase 3 | Switzerland |
3 | NCT05740007 (ClinicalTrials.gov) | March 2023 | 13/2/2023 | Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pa ... | Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tol ... | Interstitial Cystitis;Bladder Pain Syndrome | Drug: IW-3300 rectal foam;Drug: Placebo | Ironwood Pharmaceuticals, Inc. | NULL | Recruiting | 18 Years | 70 Years | All | 300 | Phase 2 | United States |
4 | NCT04734106 (ClinicalTrials.gov) | March 2023 | 27/1/2021 | Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, ... | Interstitial Cystitis;Chronic Interstitial Cystitis;Bladder Pain Syndrome | Drug: Desert Harvest Aloe Vera Capsules;Other: Placebo Capsules | Wake Forest University Health Sciences | Desert Harvest | Not yet recruiting | 18 Years | N/A | All | 100 | Early Phase 1 | United States |
5 | NCT05062902 (ClinicalTrials.gov) | January 1, 2023 | 16/9/2021 | A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin In ... | An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin I ... | Interstitial Cystitis;Chronic Pain;Pelvic Floor; Relaxation;Pelvic Floor Disorders | Device: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device;Drug: Botulinum Neurotoxin Device: High Density Surface Electromyographic, precision botulinum neurotoxininjection guidance med ... | HillMed Inc. | Baylor College of Medicine;University of Houston | Not yet recruiting | 18 Years | 60 Years | Female | 46 | Early Phase 1 | United States |
6 | NCT05658874 (ClinicalTrials.gov) | December 1, 2022 | 23/11/2022 | A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain | A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain | Interstitial Cystitis | Drug: Multimodal Bundle Drugs;Procedure: Operative Cystoscopy;Behavioral: Behavioral health consultation/therapy;Other: Pelvic floor physical therapy;Other: Usual Urogynecologic care;Drug: Bladder Instillation;Drug: Vaginal estrogen;Drug: Methenamine;Drug: Amitriptyline/Gabapentin Drug: Multimodal Bundle Drugs;Procedure: Operative Cystoscopy;Behavioral: Behavioral health consulta ... | Jocelyn Fitzgerald | NULL | Recruiting | 18 Years | 99 Years | Female | 80 | Phase 3 | United States |
7 | NCT05141006 (ClinicalTrials.gov) | March 29, 2022 | 19/11/2021 | Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Pa ... | A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Arm Study to Assess the Safety and Efficacy of a Single Treatment of BOTOX, Followed by an Optional Open-Label Treatment With BOTOX, in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Arm Study to Assess the Safety ... | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Drug: BOTOX;Drug: Placebo for BOTOX | Allergan | NULL | Recruiting | 18 Years | 75 Years | Female | 80 | Phase 2 | United States;Canada |
8 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial ... | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. Participants will be randomly assigned to splatast group or control group. In splatast group, splatas ... | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |
9 | ChiCTR2100051474 | 2021-09-15 | 2021-09-24 | Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitis and correlation with clinical characteristics Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitisand correlation with ... | Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitis and correlation with clinical characteristics Urinary Galectin-3 and CXCL-7 as biomarkers for diagnosing interstitial cystitisand correlation with ... | interstitial cystitis | Gold Standard:Suprapubic pain, pressure or discomfort, pressure, or discomfort related to bladder filling, accompanied by urgency, frequency, etc., for more than 6 months.;Index test:Both interstitial cystitis patients with or without Hunner’s ulcers were recruited in the study, while healthy subjects were involved as controls. Then we collected urine samples from all the involved subjects, and the CXCL-7 level and Galectin-3 level in the supernatants of urine were measured by ELISA. ; GoldStandard:Suprapubic pain, pressure or discomfort, pressure, or discomfort related to bladder fil ... | Hebei People's Hospital | NULL | Pending | Both | Target condition:50;Difficult condition:50 | China | |||
10 | NCT05147779 (ClinicalTrials.gov) | September 12, 2021 | 29/11/2021 | Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Inters ... | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment ... | Erectile Dysfunction;Peyronie's Disease;Interstitial Cystitis | Biological: AlloRx | The Foundation for Orthopaedics and Regenerative Medicine | NULL | Recruiting | N/A | N/A | All | 20 | Phase 1 | Antigua and Barbuda |